Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Precision BioSciences Inc

3 High-Potential Biotech Stocks Under $10

The biotech industry is witnessing rapid growth owing to its increasing demand and the inclusion of technological advancements. In this wake, investors could consider adding pocket-friendly biotech stocks Fulcrum Therapeutics (FULC), BioCryst Pharmaceuticals (BCRX), and Precision BioSciences (DTIL) to their portfolio. Continue to read….

StockNews.com · Aug 27, 2024

Invest in These 3 Biotech Stocks Today

With the biotech industry experiencing significant growth due to the increasing demand for healthcare solutions, fundamentally sound stocks such as Amicus Therapeutics (FOLD), POINT Biopharma Global (PNT), and Precision BioSciences (DTIL) might have the potential to provide substantial returns for investors and could be valuable portfolio additions this month. Learn…

StockNews.com · May 23, 2023

Why Precision BioSciences Shares Are Surging Today

Precision BioSciences Inc (NASDAQ:DTIL) has entered into an exclusive worldwide in vivo gene editing research and development collaboration and license agreement with Novartis AG (NYSE:NVS) Precision will develop a custom ARCUS nuclease that will be designed to insert, in vivo, a therapeutic transgene at a "safe harbor" location in the genome as a potential one-time…

Benzinga · Jun 22, 2022

From analysis to the latest developments in health,
read the most diverse news in one place.

BMO Sees 'Differentiated Gene Editing Platform' For This Small-Cap Stock

BMO Capital Markets initiated the coverage on Precision BioSciences Inc (NASDAQ:DTIL) with an Outperform rating and a price target of $7. The analyst said the thesis is based on: The company's proprietary gene-editing platform, whose mechanism is differentiated in a CRISPR-dominated space, offers several advantages. A diversified pipeline. Asymmetric risk/reward skewed to the upside.…

Benzinga · Jun 17, 2022

Precision BioSciences Highlights Interim Data From Allogeneic CAR T Programs In Blood Cancer Patients

Precision BioSciences Inc (NASDAQ:DTIL) shared new interim data from the Phase 1/2a study of PBCAR0191 for the patient population with aggressive lymphomas. The data demonstrated that PBCAR0191 produced high clinical response rates in CAR T relapsed patients who received a median of five prior lines of therapy. Evaluable subjects in the study had…

Benzinga · Jun 8, 2022

Lannett And 4 Other Penny Stocks Bought By Insiders

US stock futures traded higher this morning on Tuesday. Investors, meanwhile, focused on some notable insider trades When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or…

Benzinga · Mar 22, 2022

Coverage From

Organisations

Precision BioSciences

11 stories

DTIL

10 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Read news from The Economist, FT, and more,
with one subscription

Places

United States

424,523 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.